Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 2/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.49 |
| ▸ | UTRN | P46939 | 2/20 | 0.48 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.47 |
| ▸ | CEPT1 | Q9Y6K0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26686931 | 0.88 | NPC1 (0.64) | NPC1KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL28173331 | 0.86 | HDAC6 (0.62) | NPC1KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL26686820 | 0.84 | NPC1 (0.61) | NPC1KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL24454865 | 0.83 | NPC1 (0.76) | NPC1KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL19380064 | 0.82 | NPC1 (0.64) | NPC1KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL26686912 | 0.82 | NPC1 (0.64) | NPC1KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL19380236 | 0.82 | NPC1 (0.67) | NPC1KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL19380142 | 0.82 | NPC1 (0.64) | NPC1KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL26686935 | 0.82 | NPC1 (0.59) | NPC1KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL26686711 | 0.81 | NPC1 (0.71) | NPC1KDM4EALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022122-A1 | NOVEL COMPOUND FOR INHIBITING NAMPT, AND COMPOSITION INCLUDING SAME | CHECKMATE THERAPEUTICS INC. (KR) | 2026-01-22 | — | — | US | disclosed |
| WO-2023229346-A1 | NOVEL COMPOUND FOR INHIBITING NAMPT, AND COMPOSITION INCLUDING SAME | 주식회사 체크메이트테라퓨틱스 | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022122-A1 | NOVEL COMPOUND FOR INHIBITING NAMPT, AND COMPOSITION INCLUDING SAME | NAMPT, NAPRT, NNT | NPC1 57/4885KDM4E 2601/4885ALDH1A1 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.